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What is already known on this subject? 26 
Previous studies have demonstrated that several clinical risk factors are associated with outcome and 27 
the risk of parenteral nutrition/intestinal failure-related major complications in patients on long-term home 28 
parenteral nutrition. However, no objective indicator has yet been identified to categorize the severity of 29 
chronic intestinal failure. 30 
What are the new findings? 31 
The one-year odds of death, major complications of parenteral nutrition/intestinal failure (liver 32 
disease and catheter-related blood stream infection), and of weaning from home parenteral nutrition are 33 
independently associated with the type and volume of the intravenous supplementation required. 34 
How might it impact on clinical practice in the foreseeable future? 35 
The type and the volume of the intravenous supplementation could be indicators to categorize the 36 
severity of chronic intestinal failure in clinical and research settings.  37 
Abstract 38 
Background and aim 39 
No marker to categorize the severity of chronic intestinal failure (CIF) has yet been developed.  A 40 
one-year international survey was carried out to investigate whether the European Society for Clinical 41 
Nutrition and Metabolism (ESPEN) clinical classification of CIF, based on the type and the volume of the 42 
intravenous supplementation (IVS), could be an indicator of CIF severity. 43 
 Methods  44 
At baseline, participating home parenteral nutrition (HPN)-centers enrolled all adults with CIF due to 45 
non-malignant disease; demographic data, body mass index, CIF mechanism, underlying disease, HPN 46 
duration and IVS category  were recorded for each patient. The type of IVS was classified as fluid and 47 
electrolyte alone (FE) or parenteral nutrition admixure (PN). The mean daily PN volume, calculated on a 48 
weekly basis, was categorized as: <1, 1-2, 2-3, >3 L/day. The severity of CIF was determined by patient 49 
outcome (still on HPN, weaned from HPN, deceased) and the occurrence of major HPN/CIF-related 50 
complications: intestinal failure associated liver disease (IFALD), catheter-related venous thrombosis (CVC-51 
VT) and catheter-related bloodstream infection (CRBSI). 52 
Results 53 
Fifty-one HPN-centers included 2194 patients. Multiple regression analysis showed that both IVS type 54 
and volume were independently associated with the odds of weaning from IVS (higher for PN <1 L/day than 55 
for FE and all PN of >1 L/day), patient’s death (higher for PN 2-3 and >3 L/day than for FE), presence of 56 
IFALD-cholestasis/liver failure and occurrence of CRBSI (progressively higher for PN 2-3 and PN >3 L/day 57 
than for FE).  58 
Conclusions  59 
The type and the volume of the IVS required by patients with CIF could be indicators to categorize 60 
the severity of CIF in both clinical practice and research protocols.  61 
Introduction 62 
Intestinal failure (IF) is defined as the reduction of gut function below the minimum necessary for the 63 
absorption of macronutrients and/or water and electrolytes, such that intravenous supplementation (IVS) is 64 
required to maintain health and/or growth [1]. Chronic intestinal failure (CIF) is a long-lasting condition that 65 
may be reversible or irreversible. Patients with CIF are metabolically stable and receive IVS at home (home 66 
parenteral nutrition, HPN) for months, years or lifelong [2]. Single or multicenter, mostly retrospective, 67 
surveys have described risk factors associated with the patient’s outcome, such as survival and reversibility 68 
of CIF, and with the risk of HPN/IF-related major complications [3-5]. However, no simple indicator, such as 69 
creatinine for kidney disease and SaO2 for respiratory disease, has yet been identified to categorize the 70 
severity of CIF. Such an indicator would be a useful criterion for both clinical practice and research 71 
protocols.  72 
The European Society for Clinical Nutrition and Metabolism (ESPEN) devised a clinical classification of 73 
CIF, to facilitate communication among professionals through an objective categorization of the patients. 74 
This was based on patients' requirements for energy and volume of IVS and originally comprised 16 75 
categories [1]. An international cross-sectional survey was carried out to investigate the applicability of this 76 
classification and to evaluate factors associated with the IVS requirements of individual patients [6]. In 77 
adult patients with CIF due to non-malignant disease (benign-CIF), the loss of intestinal function appeared 78 
more comprehensively represented by IVS volume requirement than by energy requirement.  The results 79 
enabled the derivation of a new simplified 8-category classification of CIF, based on two types of IVS, either 80 
fluid and electrolyte alone (FE) or parenteral nutrition admixture containing energy (PN), and four 81 
categories of volume [6]. 82 
In order to determine whether ESPEN clinical classification categories could be used as indicators of 83 
the severity of CIF, a prospective, multi-center international study was carried out to investigate their 84 
association with the patient’s outcome and the major complications related to HPN/IF. The results of one-85 
year of follow up are reported. 86 
  87 
Material and methods 88 
Study design 89 
This was an international survey involving the retrospective analysis of data prospectively recorded 90 
during a one-year follow-up period. The severity of CIF was based on both patient outcome and major 91 
complications related to HPN/IF. The patient’s outcome was categorized as still on IVS, weaned from IVS or 92 
deceased. The HPN/IF-related complications were described as the occurrence of intestinal failure 93 
associated liver disease cholestasis (IFALD-cholestasis) and of central venous catheter associated vein 94 
thrombosis (CVC-VT) or central venous catheter related bloodstream infection (CRBSI) at one-year follow-95 
up [2]. 96 
Baseline HPN center enrollment and patient inclusion  97 
The baseline data collection was performed on March 1st, 2015. Details regarding HPN center 98 
enrollment and the patient inclusion criteria have been published in the previous cross-sectional survey 99 
carried out to evaluate the applicability the clinical classification of CIF [4]. Sixty-five HPN centers from 22 100 
countries enrolled all adult patients (≥18 years old) dependent on IVS for CIF on March 1st ,2015. Patients 101 
with either benign or malignant disease were included. Patients with active malignant disease were termed 102 
as having “cancer-CIF”. Patients without malignant disease at time of inclusion in the study were termed as 103 
having “benign-CIF”. Invasive intra-abdominal desmoid disease was included in the benign group, because 104 
of the chronic nature of the condition and reflecting the fact that it is an established indication for intestinal 105 
transplantation [2]. A total of 3239 patients, 9.9% with cancer-CIF and 91.1% with benign-CIF were included 106 
[4]. For the purpose of the present study, only patients with benign-CIF were investigated. 107 
Follow up data collection 108 
The one-year follow up was carried out on patients enrolled in the 2015 baseline cross-sectional 109 
study. In February 2016, the study coordinator (LP) sent an email to the HPN centers that participated in 110 
the 2015 cross-sectional survey, to invite them to participate in the follow up. The study protocol and the 111 
structured database for the data collection were attached to the invitation letter. Centers were asked to 112 
include relevant data from the patient’s medical records between March 1st 2015 and March 1st 2016 and 113 
details of the patient’s outcome on March 1st 2016.  114 
Data were collected into a structured questionnaire embedded in an Excel (Microsoft Co., 2013) 115 
database (the ESPEN CIF Action Day database). The items of the questionnaire are shown in Table 1.  116 
Ethical statement 117 
The study was approved by the Home Artificial Nutrition and Chronic Intestinal Failure (HAN&CIF) 118 
special interest group of ESPEN. The research was based on anonymized information taken from patient 119 
records at time of data collection. The study was conducted with full regard to confidentiality of the 120 
individual patient. Ethical committee approval was obtained by the individual HPN centers according to 121 
local regulations. The collected data were used only for the study purpose. Contributing centers have been 122 
anonymized for data analysis and presentation. 123 
Statistical analysis 124 
Data are reported as mean ± standard deviation (SD), median and range, absolute and relative 125 
frequencies. For bivariate analysis involving categorical variables non-parametric tests such as Pearson’s chi 126 
squared or Fisher’s exact test were used, while in case of a categorical and a continuous variable the 127 
parametric one-way ANOVA (analysis of variance) or the non-parametric Kruskal-Wallis test were 128 
performed. 129 
Logistic regression was carried out for multivariate analysis. The odds ratio was used to measure the 130 
association between the variables and the patient outcome or the presence of HPN/IF-complications. Two-131 
tailed p values less than 0.05 were considered as statistically significant. 132 
The analyses were performed using the IBM SSPS Statistics package for Windows, version 23.0 (BM 133 
Co., Armonk, NY, USA) and the R software for Windows, version 3.5.1 (http://cran.r-project.org).   134 
Results  135 
Study population 136 
Fifty-one of the 65 HPN-Centers which contributed in the 2015 database collection, participated in 137 
the 2016 follow up; this included 2194 of the 2919 benign-CIF (75.1%) patients enrolled in 2015. Most of 138 
the patients (79.7%) were from European Countries, the remaining were from Israel, US, Mexico, Argentina, 139 
Brazil and Australia. The mean number of patients included in the follow up by center was 43.0 ± 54.1 140 
(median: 19; range: 1-231). 141 
Table 2 shows the baseline characteristics of the cohort of patients with benign-CIF included in the 142 
present study. Two-thirds were female. The median (range) patient age, BMI and IVS duration were 56.5 143 
years (18.0-98.0), 21.7 kg/m2 (10.5-59.6) and 33.2 months (0-474), respectively. SBS-J was the most 144 
frequent pathophysiological mechanism of IF (35.9% of cases). The most frequent underlying disease was 145 
Crohn’s disease (21.1%). 146 
 The type of IVS was FE in 7.9% of patients and PN in 92.1%. The IVS volume was significantly lower in 147 
the subgroup of patients receiving FE (median 857.1 mL/day, range 107.1–4800.0) than in those receiving 148 
PN (median 1785.7 mL/day, range 81.7-7542.8) (P<0.001). 149 
One-year outcome 150 
At March 1st, 2016, 1740 (79.3%) patients were still on IVS, 298 (13.6%) were weaned from IVS and 151 
156 (7.1%) were deceased. The reason for weaning from IVS was reported in 272 cases:  spontaneous 152 
intestinal adaptation in 138 (50.7%), non-transplant surgery in 114 (41.9%); surgical intestinal continuity 153 
reconstruction in 97 cases), ITx in 14 (5.1%) and intestinal growth factor therapy in 6 (2.2%) cases. The 154 
cause of death was reported in 146 cases: HPN/IF-related in 6 (4.1%) patients (CRBSI 5, IFALD 1), underlying 155 
disease-related in 64 (43.8%) (4 due to ITx complications) and other causes (neither HPN/IF nor underlying 156 
disease-related) in 76 (52.1%) cases. The bi-variate analysis (Table 3) showed that the patient’s outcome 157 
was associated with the patient’s age and BMI, the duration of IVS, the mechanism of IF, the underlying 158 
disease and the IVS categories (either FE or PN).  159 
Presence or occurrence of HPN/IF-complications at the end of the one-year follow up 160 
This item was recorded in 1859 of the 2194 (84.7%) patients. The presence of IFALD-cholestasis/liver 161 
failure was reported in 97 patients (4.4%): cholestasis 63 (64.9%), impending liver failure 11 (11.3%), overt 162 
liver failure 18 (18.6%), not specified 5 (5.1%). A CVC-VT was present in 53 patients (2.9%), 30 of which 163 
occurred during the one-year follow up. During the follow up, 273 patients (14.7%) had 344  episodes of 164 
CRBSI: one episode in 224 (82.0%); two episodes in 40 (14.7%); three episodes in 5 (1.8%); four episodes in 165 
2 (0.7%); 7 and 10 episodes in 1 (0.4%) patient each one. The bi-variate analysis (Table 4) showed that: the 166 
presence of IFALD-cholestasis/liver failure was associated with the patient’s gender and with both the CIF 167 
clinical classification categories of IVS and the type of IVS. The presence of CVC-VT was associated with the 168 
duration of IVS, the mechanism of IF and the CIF clinical classification categories of IVS. The occurrence of 169 
CRBSI was associated with the patient’s age and BMI, the underlying disease and with both the CIF clinical 170 
classification categories of IVS and the type of IVS. 171 
 172 
Multivariate analysis of factors associated with the patient’s one-year outcome and HPN/IF-173 
complications 174 
Weaning from IVS, death, presence of IFALD-cholestasis/liver failure or CVC-VT at the end of the 175 
follow up, and occurrence of CRBSI during the one-year of follow up were considered the dependent 176 
variables. The baseline demographics, IF mechanism, underlying disease and IVS characteristics were 177 
included as independent variables.  178 
The association with either the IVS type or the IVS volume was investigated through two models of 179 
analysis: 180 
a) the IVS type model, to analyze the association with either FE or PN; because of the statistically 181 
significant differences between the total FE and the total PN groups observed in the bivariate 182 
analyses, as well as of the low number of patients receiving the FE type, in this analysis the total FE 183 
group was considered the comparator group to be compared with the four PN groups; 184 
b) the PN volume model, to analyze the association with the volume of the PN type of IVS; in this model, 185 
only patients receiving PN were included in the analysis and the lowest PN volume (PN1) was 186 
considered as the comparator group 187 
 188 
One-year outcome odds (Tables 5 and 6) 189 
In the whole group of patients, the odds of weaning from IVS (Table 5): a) were higher in the smallest 190 
PN1 type category (mean volume: 695.3 ± 216.8 mL/day) than in the FE type category (mean volume: 191 
1055.8 ± 859.6 mL/day, P<0.001), while no difference was observed between FE and the other PN volume 192 
categories; b) were lower in the greatest PN volume categories (PN2, PN3 and PN4), in comparison with 193 
PN1, the smallest PN volume; c)  were similar between the two models for all  the other independent 194 
factors: they were lower in the oldest decades of age, in the longest duration of IVS categories, in the 195 
miscellaneous group of underlying diseases and were higher in the underweight, overweight and obese 196 
BMI categories. . The multivariate analysis for the odds of weaning from IVS was repeated after excluding 197 
those patients who were weaned because of a non-transplant surgical procedure (Table 6). The results 198 
confirmed the higher odds associated with the PN1 IVS, the patient’s age and duration of IVS, but not with 199 
the patient’s BMI. Significant lower odds of weaning were observed in patients who had SBS-J or SBS-JC as 200 
mechanisms of IF and in those who had an underlying disease categorized in the miscellaneous group. 201 
The odds of death on IVS: a) were higher in all the PN volume categories in comparison with the FE 202 
type category, even though this was statistically significant only with the greatest PN volumes, but no 203 
association was observed when only the PN volume categories were compared; b) were similar between 204 
the two models for all the other independent factors: they were higher in the oldest age categories, in the 205 
lowest BMI categories; in comparison with SBS-J mechanism of IF, the odds of death were lower in the SBS-206 
JC group and were higher in with the other mechanisms of IF, excepting the extensive mucosal disease; the 207 
likelihood of death was increased in the mesenteric ischemia and decreased in the CIPO groups of 208 
underlying disease. 209 
 210 
Odds of major complications of HPN/IF (Table 7)  211 
The odds of the presence of IFALD-cholestasis/impending or overt liver failure: a) were progressively 212 
higher in the greatest PN volume categories (PN3 and PN4), in comparison to both the FE type of IVS and 213 
the PN1 and PN2 volumes; b) were similar between the two models of analysis for all the other 214 
independent factors: in comparison with SBS-J, the likelihood of IFALD was lower in dysmotility mechanism 215 
of IF and higher in the group with surgical complications as their underlying disease.  216 
The odds of the presence of CVC-VT: a) showed no association with the IVS categories; b) were 217 
similar between the two models of analysis for all the other independent factors: they were higher in the in 218 
the longest IVS duration categories and in the underweight category of BMI. 219 
The odds of the occurrence of an episode of CRBSI: a) were progressively higher with the increase of 220 
the volume of the PN in comparison to both the FE type of IVS and the PN1 and PN2 volumes ; b) were 221 
similar between the two models of analysis for all the other independent factors: they were lower in older 222 
patients and were higher in the obese category of BMI and in the CIPO underlying disease   223 
Discussion 224 
This is the first study aimed at investigating the association between IVS requirement, CIF outcome 225 
and the occurrence of major complications in a very large international cohort of IVS-dependent patients 226 
with CIF due to benign underlying disease. The results show that both the type and the volume of the IVS 227 
are independently associated with the odds of weaning from IVS at one-year, as well as with the risk of 228 
mortality, the occurrence of CRBSI and the presence of IFALD-cholestasis/liver failure. In patients with CIF, 229 
the type and the volume of the IVS requirement primarily depends on the degree of the reduction of gut 230 
function (6). However, other factors may be involved, such as the patient’s metabolic condition and vital 231 
organ function, the patient’s compliance with the prescribed treatment as well as the treatment protocols 232 
of the multidisciplinary team caring for him/her (1,2). Therefore, while any association between IVS 233 
characteristics and the patient’s outcome or the occurrence of HPN/IF complications may not be 234 
considered causal, they may indicate that the type and the volume of the IVS reflect comprehensive odds of 235 
morbidity and mortality for IVS-dependent patients, independently from the factors that may have 236 
determined their prescription. This is further strengthened by the observation that none of the other 237 
independent factors entered in the multiple regression analyses was contemporaneously associated with 238 
odds of weaning from IVS, death, or occurrence of IFALD and CRBSI. These data support the potential role 239 
of the ESPEN clinical classification of CIF, based on the type and the volume of the IVS, as a potential 240 
indicator of CIF severity. Further follow up surveys are required to investigate if this could be translated 241 
inot a long-term marker of CIF. 242 
The one-year odds of death depended on the interaction between the IVS type and volume rather 243 
than on either characteristic alone. Indeed, an increased likelihood of death was observed in those 244 
receiving the greatest volumes of PN rather than those receiving the FE, but no association was found with 245 
PN-volume alone; since HPN-related deaths were very rare (3), these results would suggest a less severe 246 
clinical condition in patients with CIF requiring only FE supplementation.  247 
The one-year likelihood of weaning from IVS was associated with both the type and volume of IVS. 248 
The PN1 volume (≤1 L/day) showed higher odds of weaning than either the greater PN-volumes or FE-type 249 
IVS. There could be several reasons for a longer maintenance of low volume FE than of low volume PN IVS: 250 
a more difficult intestinal rehabilitation of fluid and electrolytes than of macronutrient absorption due to 251 
concomitant secondary mechanisms of IF causing increased intestinal secretion (1); the concomitant 252 
presence of reduced kidney function requiring the maintenance of optimal hydration (2,7); physician’s 253 
and/or patient’s  perception of a lower risk of IVS-associated complications with FE than with PN; patient’s 254 
better acceptance of FE than of PN, because of shorter duration of FE infusion compared to PN (2); the 255 
lower cost of FE. All of these factors would make weaning from FE slower/less likely than weaning from PN.  256 
The likelihoods of IFALD and of the occurrence of CRBSIs were also associated with both the type and 257 
the volume of the IVS, whereas no association was observed with the presence of CVC-VT (Tables 4 and 7). 258 
The odds of IFALD and of CRBSI were greater in patients receiving the highest volumes of PN in comparison 259 
with the lowest PN-volumes and the FE-type of IVS. Furthermore, there was a progressive increase in 260 
likelihood of these complications with increased PN volume.  These data are in keeping with previous 261 
studies (2,8,9). The pathogenesis of IFALD is multifactorial, including factors related to the IVS, underlying 262 
gastrointestinal disease and systemic factors, especially episodes of sepsis (2,10). Intravenous 263 
supplementation, overfeeding and a high amount of lipid emulsion are recognized causes of IFALD (2,10). 264 
Similarly, CRBSI occurrence has also previously been reported to occur more frequently in those dependent 265 
on an increased number of days of IVS (8); this may relate to more frequent handling of the central venous 266 
catheter increasing infection risk or the association between macronutrients, vitamins and trace metals 267 
affecting microbial growth in the PN admixture (11,12). 268 
Most of the other independent factors found to be associated with patient’s outcome and HPN/IF 269 
complications (Tables, 5,6,7) were in keeping with data from previous studies (2,3,8,10). As expected, non-270 
transplant surgery was the cause of weaning off HPN in a large percentage of patients (13). Notably, data 271 
on the causes of death on long-term IVS are consistent with previous observations (3-5,13-15), even though 272 
the percentage of HPN-related deaths (4%) was lower than that reported in longer retrospective surveys 273 
(10-14%) (3-5,13-15). This could be due to the short duration of the present follow up, as it is known that 274 
the rate of the HPN-related death increases with the duration of the treatment (4). The 344 episodes of 275 
CRBSI registered in the 1859 patients accounted for a rate of CRBSI of 0.18 per catheter-year, or 0.50 per 276 
1000 catheter-days, a rate that is in the range reported in the literature (2). The 30 new cases of CVC-VT 277 
observed at one-year follow up, accounted for an incidence rate of 0.016 per catheter-year, that is also in 278 
the lower range of the literature (0.02-0.09 cases per catheter-year) (2).  279 
The weakness of the study is mainly represented by the retrospective analysis of data prospectively 280 
recorded in the previous 12 months, which would imply a risk of some underreporting. However, the 281 
strength of the study is clearly reflected by its international multicenter structure and by the study 282 
population, which is the largest cohort of patients with CIF ever enrolled in a single survey. These 283 
characteristics should avoid the potential bias associated with the analysis of individual center cohorts, 284 
which could be influenced by local practice and expertise, and mitigate the impact of the above possible 285 
weakness on statistical analyses. Furthermore, the agreement between our results and the risk factors, 286 
(other than quantified IVS), reported by previous studies would support the overall reliability of our 287 
findings. 288 
In conclusion, the type of the IVS, either FE or PN, and the volume of the PN-admixture, as 289 
categorized by the ESPEN clinical classification of CIF, were found to be independently associated with the 290 
one-year likelihoods of death, of weaning from HPN and of major complications of HPN/IF. These results 291 
support the ESPEN categorization of the IVS as potential marker of the severity of CIF.  292 
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Table 1. Items of the “Chronic Intestinal Failure (CIF) Action Day” database of the European Society for 373 
Clinical Nutrition and Metabolism (ESPEN) used for the follow up survey on patient outcome and home 374 
parenteral nutrition/chronic intestinal failure major complications. 375 
______________________________________________________________________________________ 376 
At baseline  377 
 Patient characteristics  378 
 Gender 379 
 Age (year) 380 
 Body height (cm) 381 
 Body weight (kg) 382 
 Body mass index (BMI) [body weight (kg)/height (m2)] 383 
 CIF characteristics  384 
 Pathophysiological mechanism of intestinal failure 385 
 Short bowel syndrome with end-jejunostomy (SBS-J) 386 
 SBS with jejuno-colic anastomosis (SBS-JC) 387 
 SBS with jejuno-ileal anastomosis and total colon in continuity (SBS-JIC) 388 
 Dysmotility 389 
 Intestinal fistulas (Fistulas) 390 
 Mechanical obstruction (Obstruction)  391 
 Extensive small bowel mucosa disease (Mucosal disease) 392 
 Underlying disease which causes the intestinal failure  393 
 HPN program characteristics 394 
 HPN duration at patient first inclusion in the database (months) 395 
 Intravenous supplementation (IVS)-admixture type 396 
 IVS-volume per day of infusion 397 
 IVS-total energy per day of infusion 398 
 IVS-days of infusion per week 399 
 400 
 Clinical classification of CIF, based on the IVS type and volume: 401 
 Volume of the IVS (mL/day)* 
Type of the IVS ≤ 1000 1001 - 2000 2001 - 3000 > 3000 
Fluids and electrolytes (FE) FE 1 FE 2 FE 3 FE 4 
Parenteral nutrition (PN)  PN 1 PN 2 PN 3 PN 4 
 * calculated as daily mean of the total volume infused per week = volume per day of infusion x number 402 
of infusions per week / 7 403 
 FE, Fluids and Electrolytes alone 404 
 PN, Parenteral Nutrition Admixture containing also macronutrients 405 
 406 
 407 
 408 
At follow up 409 
Patient outcome 410 
 Still on HPN: 411 
 On standard treatment 412 
 On intestinal growth factor 413 
 After intestinal transplantation (ITx) 414 
 Weaned from HPN: 415 
 spontaneous adaptation 416 
 non-transplant surgery 417 
 intestinal growth factor therapy 418 
 ITx 419 
 Deceased: 420 
 HPN/CIF complication (CRBSI,  CVC-VT,  IFALD-cholestasis) 421 
 underlying disease complication ( gastrointestinal disease, systemic disease, post-ITx complications 422 
or other) (specify) 423 
 other causes (specify) 424 
 Lost to follow up 425 
HPN/IF major complications 426 
 Presence of intestinal failure associated liver disease-cholestasis (IFALD-cholestasis) or liver failure: 427 
 Cholestasis: total bilirubin >1 mg/dL (>17.1 mol/L) and direct bilirubin >0.3 mg/dL (>5.2 428 
mol/L) 429 
 Impending liver failure: total bilirubin >3 mg/dL (>54.3 mol/L) with direct bilirubin above the 430 
upper normal value, progressive thrombocytopenia and splenomegaly  431 
 Overt liver failure: portal hypertension, hepatosplenomegaly, hepatic fibrosis or cirrhosis 432 
 Presence of central venous catheter venous-associated venous thrombosis (CVC-VT) 433 
 Occurrence of catheter related bloodstream infection (CRBSI), diagnosed according to local 434 
protocol, between baseline and follow up 435 
_______________________________________________________________________________________ 436 
  437 
Table 2. Baseline patient cohort characteristics  438 
Categories  N. of patients (%)  Mean ± SD 
     
Gender  
 
  
Male  811 (37.0)   
Female  1383 (63.0)   
 
 
 
  
Age (years)  
 
 55.1 ± 16.2 
≤29  187 (8.5)   
30-49  575 (26.2)   
50-69  990 (45.1)   
≥70  442 (20.1)   
     
BMI (kg/m2)  
 
 22.3 ± 4.4 
≤15    57 (2.6)   
15-18.5  324 (14.8)   
18.5-25  1334 (60.8)   
25-30  363 (16.5)   
≥30  111 (5.1)   
Missing       5 (0.2)   
     
Duration of IVS (years)  
 
 4.8± 5.8 
≤1  575 (26.2)   
1-3  575 (26.2)   
3-10  748 (34.1)   
>10  293 (13.4)   
Missing       3 (0.1)   
     
Mechanism of IF  
 
  
SBS-J  788 (35.9)   
SBS-JC   459 (20.9)   
SBS-JIC   140 (6.4)   
Fistulas   149 (6.8)   
Dysmotility  398 (18.1)   
Obstruction   104 (4.7)   
Mucosal disease  156 (7.1)   
 
 
 
  
Underlying disease  
 
  
Crohn's disease  462   
Ulcerative colitis    18   
     Total IBD  480 (21.9)   
     Mesenteric ischemia  395 (18.0)   
     Surgical complications  306 (13.9)   
CIPO primary  222   
CIPO secondary    77   
     Total CIPO   299 (13.6)   
Intra-abdominal adhesions    72   
Volvulus    46   
Cured cancer    21   
Abdominal trauma    26   
Intestinal malformation    13   
     Total other causes of SBS  178 (8.1)   
Collagenous    40   
Intra-abdominal desmoid    22   
Intestinal polyposis    16   
Autoimmune enteropathy    14   
Neurological disease    11   
Congenital mucosal disease foglio2    14   
Celiac disease      8   
Other diseases    93   
     Total miscellaneous  218 (9.9)   
     Radiation enteritis  164 (7.5)    
Missing  154 (7.0   
     
Clinical classification of CIF (volume/day of infusion) 
FE1 ( ≤1 L)  118 (5.4)   
FE2 (1-2 L)    40 (1.8)   
FE3 (2-3 L)    10 (0.5)   
FE4 ( >3 L)      6 (0.3)   
     Total FE  174 (7.9)  1055.8 ± 859.6 
PN1 ( ≤1 L)  384 (17.5)   
PN2 (1-2 L)  944 (43.0)   
PN3 (2-3 L)  482 (22.0)   
PN4 ( >3 L)  210 (9.6)   
     Total PN  2020 (92.1)  1872.6 ± 972.1 
     
BMI, body mass index; HPN, home parenteral nutrition; IF, intestinal failure; SBS-J, short bowel syndrome 439 
with jejunostomy; SBS-JC, short bowel syndrome with jejuno-colon anastomosis with partial colon; SBS-JIC, 440 
short bowel syndrome with jejuno-ileo anastomosis with intact colon; IBD, inflammatory bowel disease, 441 
CIPO, chronic intestinal pseudo-obstruction; CIF, chronic intestinal failure; FE, fluid and electrolytes alone; 442 
PN, parenteral nutrition-admixture 443 
 444 
Table 3. Bivariate analysis of factors associated with the one-year outcome of adult patients on home intravenous support for chronic intestinal failure due to 445 
benign disease. 446 
 
Patients 
 
Still on HPN  Weaned from HPN  Deceased   
 n.  n. (%)  n. (%)  n.  (%)  P 
          
Gender (n.)  
  
 
 
 
  
0.144 
Male 811 
 
627 (77.3)  125 (15.4)  59 (7.3) 
  
Female 1383 
 
1113 (80.5)  173 (12.5)  97 (7.0) 
  
 
 
  
 
 
 
   
Age (years)  
  
 
 
 
  
<0.001 
≤29 187 
 
147 (78.6)  37 (19.8)  3 (1.6) 
  
30-49 575 
 
462 (80.3)  93 (16.2)  20 (3.5) 
  
50-69 990 
 
794 (80.2)  124 (12.5)  72 (7.3) 
  
≥70 442 
 
337 (76.2)  44 (10.0)  61 (13.8) 
  
          
BMI (kg/m2)  
  
 
 
 
  
0.008 
≤15 57 
 
46 (80.7)  6 (10.5)  5 (8.8) 
  
15-18.5 324 
 
241 (74.4)  51 (15.7)  32 (9.9) 
  
18.5-25 1334 
 
1100 (82.5)  146 (10.9)  88 (6.6) 
  
25-30 363 
 
274 (75.5)  68 (18.7)  21 (5.8) 
  
≥30 111 
 
75 (67.6)  27 (24.3)  9 (8.1) 
  
          
Duration of IVS (years)         <0.001 
≤1 575 
 
345 (60)  182 (31.7)  48 (8.3) 
  
1-3 575 
 
455 (79.1)  76 (13.2)  44 (7.7) 
  
3-10 748 
 
670 (89.6)  34 (4.5)  44 (5.9) 
  
>10 293 
 
268 (91.5)  5 (1.7)  20 (6.8) 
  
          
Mechanism of IF (n.) 788 
  
 
 
 
  
<0.001 
SBS-J 459 
 
617 (78.3)  115 (14.6)  56 (7.1) 
  
SBS-JC  140 
 
405 (88.2)  34 (7.4)  20 (4.4) 
  
SBS-JIC  149 
 
109 (77.9)  24 (17.1)  7 (5.0) 
  
Fistulas  398 
 
96 (64.4)  35 (23.5)  18 (12.1) 
  
Dysmotility 104 
 
325 (81.7)  43 (10.8)  30 (7.5) 
  
Obstruction  156 
 
73 (70.2)  19 (18.3)  12 (11.5) 
  
Mucosal disease 788 
 
115 (73.7)  28 (17.9)  13 (8.3) 
  
 
 
  
 
 
 
   
Underlying disease (n.)  
  
 
 
 
  
<0.001 
Total IBD 480 
 
383 (79.8)  72 (15.0)  25 (5.2) 
  
Mesenteric ischemia 395 
 
313 (79.2)  42 (10.6)  40 (10.1) 
  
Surgical complications 306 
 
215 (70.3)  63 (20.6)  28 (9.2) 
  
Total CIPO 299 
 
256 (85.6)  31 (10.4)  12 (4.0) 
  
Other causes of SBS  178 
 
176 (80.7)  21 (9.6)  21 (9.6) 
  
Miscellaneous 218 
 
136 (76.4)  32 (18.0)  10 (5.6) 
  
Radiation enteritis 154 
 
135 (82.3)  17 (10.4)  12 (7.3) 
  
 
 
  
 
 
 
   
Clinical classification of CIF (n.)  
  
 
 
 
  
0.190 
FE1 ( ≤1 L) 118 
 
106 (89.8)  11 (9.3)  1 (0.8) 
  
FE2 (1-2 L) 40 
 
31 (77.5)  5 (12.5)  4 (10.0) 
  
FE3 (2-3 L) 10 
 
8 (80)  2 (20.0)  0 
  
FE4 ( >3 L) 6 
 
5 (83.3)  1 (16.7)  0 
  
PN1 ( ≤1 L) 384 
 
296 (77.1)  65 (16.9)  23 (6.0) 
  
PN2 (1-2 L) 944 
 
745 (78.9)  126 (13.3)  73 (7.7) 
  
PN3 (2-3 L) 482 
 
378 (78.4)  65 (13.5)  39 (8.1) 
  
PN4 ( >3 L) 210 
 
171 (81.4)  23 (11.0)  16 (7.6) 
  
          
Type of IVS (n.)         0.032 
Total FE 174  150 (86.2)  19 (10.9)  5 (2.9)   
Total PN 2020  1590 (78.7)  279 (13.8)  151 (7.5)   
          
BMI, body mass index; HPN, home parenteral nutrition; IF, intestinal failure; SBS-J, short bowel syndrome with jejunostomy; SBS-JC, short bowel syndrome with 447 
jejuno-colon anastomosis with partial colon; SBS-JIC, short bowel syndrome with jejuno-ileo anastomosis with intact colon; IBD, inflammatory bowel disease, 448 
CIPO, chronic intestinal pseudo-obstruction; CIF chronic intestinal failure; IVS, intravenous supplementation; FE, fluid and electrolytes alone; PN, parenteral 449 
nutrition-admixture  450 
Table 4. Bivariate analysis of factors associated with the major home parenteral nutrition/ intestinal failure complications during a one-year follow up in adult 451 
patients on home intravenous support  for chronic intestinal failure due to non malignant disease, categorized according to clinical, home parenteral nutrition 452 
and referral center characteristics (IFALD, intestinal failure associated liver disease: cholestasis of impending/overt liver failure; CVC-VT. Central venous 453 
catheter-associated deep vein thrombosis; CRBSI, catheter related bloodstream infections) 454 
 
Patients 
Presence of 
IFALD* 
  Patients 
Presence of 
CVC-VT 
  Patients 
Occurrence 
of CRBSI 
  
 n. n. (%) P  n. n. (%) P  n. n.  (%)  P 
             
Gender (n.)  
 
0.029   
 
0.689   
  
0.886 
Male 642 46 (6.7)   667 21 (3.1)   585 102 (14.8)   
Female 1120 51 (4.4)   1139 32 (2.7)   1000 171 (14.6)   
 
            
Age (years)   0.253         0.001 
≤29 148 13 (8.1)   158 3 (1.9) 0.855  122 39 (24.2)   
30-49 456 28 (5.8)   469 15 (3.1)   404 79 (16.4)   
50-69 801 37 (4.4)   813 25 (25)   735 103 (12.3)   
≥70 357 19 (5.1)   366 10 (2.7)   324 52 (13.8)   
             
BMI (kg/m2)   0.533    0.281     0.019 
≤15 45 3 (6.3)   158 2 (4.2)   41 7 (14.6)   
15-18.5 238 16 (6.3)   469 12 (4.7)   217 37 (14.6)   
18.5-25 1075 63 (5.5)   813 27 (2.4)   986 151 (13.3)   
25-30 303 12 (3.8)   366 8 (2.5)   262 53 (16.8)   
≥30 96 3 (3.0)   158 4 (4.0)   74 25 (25.3)   
             
Duration of IVS (years)   0.980    0.010     0.549 
≤1 442 25 (5.4)   461 6 (1.3)   398 69 (14.8)   
1-3 449 23 (4.9)   463 9 (1.9)   396 76 (16.1)   
3-10 611 34 (5.3)   619 26 (4.0)   550 95 (14.7)   
>10 257 15 (5.5)   260 12 (4.4)   238 33 (12.2)   
             
Mechanism of IF (n.)   0.540    0.038     0.674 
SBS-J 633 51 (7.5)   670 14 (2.0)   584 100 (14.6)   
SBS-JC 357 15 (4.0)   352 20 (5.4)   326 45 (12.1)   
SBS-JIC 108 5 (4.4)   110 3 (2.7)   92 21 (18.6)   
Fistulas 120 5 (4.0)   124 1 (0.8)   104 21 (16.8)   
Dysmotility 335 10 (2.9)   334 11 (3.2)   291 54 (15.7)   
Obstruction 85 5 (5.6)   89 1 (1.1)   77 13 (14.4)   
Mucosal disease 124 6 (4.6)   670 3 (2.3)   111 19 (14.6)   
 
            
Underlying disease (n.)   0.156    0.060     0.023 
Total IBD 406 19 (4.5)   417 8 (1.9)   375 50 (11.8)   
Mesenteric ischemia 294 20 (6.4)   300 14 (4.5)   272 42 (13.4)   
Surgical complications 238 19 (7.4)   254 3 (1.2)   215 42 (16.3)   
Total CIPO 255 9 (3.4)   257 7 (2.7)   214 50 (18.9)   
Other causes of SBS 129 8 (5.8)   130 7 (5.1)   110 26 (19.1)   
Miscellaneous 164 13 (7.3)   169 8 (4.5)   143 34 (19.2)   
Radiation enteritis 129 3 (2.3)   130 2 (1.5)   119 13 (9.8)   
 
            
Clinical classification of IF (n.)   <0.001    0.005     0.005 
FE1 ( ≤1 L) 105 1 (0.9)   105 1 (0.9)   99 7 (6.6)   
FE2 (1-2 L) 36 1 (2.7)   37 0   33 4 (10.8)   
FE3 (2-3 L) 9 0   7 2 (22.2)   7 2 (22.2)   
FE4 ( >3 L) 5 1 (16.7)   6 0   6 0   
PN1 ( ≤1 L) 302 6 (1.9)   294 14 (4.5)   275 33 (10.7)   
PN2 (1-2 L) 768 30 (3.8)   773 25 (3.1)   678 120 (15.0)   
PN3 (2-3 L) 374 35 (8.6)   401 8 (2.0)   342 66 (16.2)   
PN4 ( >3 L) 163 23 (12.4)   183 3 (1.6)   145 41 (22.0)   
             
Type of IVS (n.)   0.050    0.452     0.016 
Total FE 155 3 (1.9)   155 2 (1.9)   145 13 (8.2)   
Total PN 1607 94 (5.5)   1701 50 (2.9)   1440 260 (15.3)   
             
             
BMI, body mass index; HPN, home parenteral nutrition; IF, intestinal failure; SBS-J, short bowel syndrome with jejunostomy; SBS-JC, short bowel syndrome with 455 
jejuno-colon anastomosis with partial colon; SBS-JIC, short bowel syndrome with jejuno-ileo anastomosis with intact colon; IBD, inflammatory bowel disease, 456 
CIPO, chronic intestinal pseudo-obstruction; CIF chronic intestinal failure; IVS, intravenous supplementation; FE, fluid and electrolytes alone; PN, parenteral 457 
nutrition-admixture 458 
 459 
  460 
Table 5. Multivariate analysis of factors independently associated with the likelihoods of weaning from IVS and of death in adult patients with CIF 461 
  Patients weaned form HPN  Patients deceased 
  
Association with 
IVS type (n. 278) 
 
Association with 
PN volume (n. 259) 
 
Association with 
IVS type (n. 147) 
 
Association with 
PN volume (n. 142) 
Independent factors  P OR  P OR  P OR  P OR 
             
IVS type and volume              
Total FE1  Comparator      Comparator     
PN1 (≤1 L)  0.002 2.726  Comparator   0.066   Comparator  
PN2 (1-2 L)  0.539   <0.001 0.428  0.025 3.001  0.665  
PN3 (2-3 L)  0.335   0.002 0.491  0.016 3.343  0.456  
PN4 (>3 L)  0.907   0.002 0.372  0.019 3.611  0.420  
             
Gender             
Male  Comparator           
Female  0.173   0.081   0.684   0.848  
             
Age (years)             
≤29  Comparator           
30-49  0.086   0.057   0.244   0.233  
50-69  0.003 0.462  0.006 0.484  0.015 4.531  0.017 4.433 
≥70  0.002 0.393  0.001 0.353  <0.001 9.602  <0.001 9.412 
             
BMI (kg/m2)             
18.5-25.0  Comparator           
≤15.0  0.281   0.338   0.063   0.074  
15.0-18.5  0.057   0.034 1.573  0.006 1.960  0.011 1.891 
25.1-30.0  0.002 1.835  0.002 1.850  0.440   0.416  
≥30.0  0.017 2.010  0.001 2.826  0.174   0.223  
             
Duration of IVS (years)             
≤1  Comparator           
1-3  <0.001 0.266  <0.001 0.268  0.545   0.411  
3-10  <0.001 0.086  <0.001 0.080  0.081   0.041 0.605 
>10  <0.001 0.028  <0.001 0.030  0.607   0.609  
             
Mechanism of IF             
SBS-J  Comparator           
SBS-JC   0.095   0.082   0.008 0.452  0.007 0.438 
SBS-JIC   0.214   0.272   0.216   0.263  
Fistulas   0.147   0.154   0.022 2.162  0.014 2.347 
Dysmotility  0.696   0.411   0.021 2.344  0.019 2.401 
Obstruction   0.391   0.300   0.043 2.333  0.045 2.335 
Mucosal disease  0.396   0.282   0.246   0.194  
 
            
Underlying disease             
Total IBD  Comparator           
Total CIPO  0.153   0.099   0.033 0.354  0.052  
Other causes of SBS  0.160   0.168   0.753   0.949  
Miscellaneous  0.008 0.436  0.011 0.442  0.866   0.704  
Mesenteric ischemia  0.298   0.483   0.025 1.946  0.013 2.164 
Radiation enteritis  0.514   0.718   0.406   0.595  
Surgical complications  0.408   0.587   0.521   0.414  
             
BMI, body mass index; HPN, home parenteral nutrition; IF, intestinal failure; SBS-J, short bowel syndrome with jejunostomy; SBS-JC, short bowel syndrome with 462 
jejuno-colon anastomosis with partial colon; SBS-JIC, short bowel syndrome with jejuno-ileo anastomosis with intact colon; IBD, inflammatory bowel disease, 463 
CIPO, chronic intestinal pseudo-obstruction; CIF chronic intestinal failure; IVS, intravenous supplementation; FE, fluid and electrolytes alone; PN, parenteral 464 
nutrition-admixture 465 
  466 
Table 6. Multivariate analysis of factors independently associated with the likelihoods of weaning from IVS without an intestinal surgical procedure in adult 467 
patients with CIF  468 
  Patients weaned form HPN  
  
Association with 
IVS type (n. 174) 
 
Association with 
PN volume (n. 162) 
 
Independent factors  P OR  P OR  
        
IVS type and volume         
Total FE1  Comparator      
PN1 (≤1 L)  0.049 2.094  Comparator   
PN2 (1-2 L)  0.862   <0.001 0.433  
PN3 (2-3 L)  0.762   0.002 0.419  
PN4 (>3 L)  0.459   0.011 0.327  
        
Gender        
Male  Comparator      
Female  0.760   0.554   
             
Age (years)        
≤29  Comparator      
30-49  0.031 0.543  0.024 0.517  
50-69  0.002 0.408  0.003 0.425  
≥70  0.001 0.296  <0.001 0.251  
        
BMI (kg/m2)        
18.5-25.0  Comparator      
≤15.0  0.367   0.420   
15.0-18.5  0.096   0.076   
25.1-30.0  0.097   0.053   
≥30.0  0.173   0.056   
        
Duration of IVS (years)        
≤1  Comparator      
1-3  <0.001 0.332  <0.001 0.320  
3-10  <0.001 0.139  <0.001 0.123  
>10  <0.001 0.047  <0.001 0.049  
        
Mechanism of IF        
SBS-J  Comparator      
SBS-JC   0.318   0.236   
SBS-JIC   <0.001 3.459  <0.001 3.684  
Fistulas   <0.001 3.387  <0.001 3.710  
Dysmotility  0.011 2.707  0.002 3.536  
Obstruction   0.049 2.387  0.026 2.762  
Mucosal disease  0.003 2.699  0.001 3.165  
 
       
Underlying disease        
Total IBD  Comparator      
Total CIPO  0.087   0.042 0.403  
Other causes of SBS  0.859   0.871   
Miscellaneous  0.013 0.427  0.013 0.417  
Mesenteric ischemia  0.237   0.338   
Radiation enteritis  0.119   0.193   
Surgical complications  0.540   0.346   
        
BMI, body mass index; HPN, home parenteral nutrition; IF, intestinal failure; SBS-J, short bowel syndrome with jejunostomy; SBS-JC, short bowel syndrome with 469 
jejuno-colon anastomosis with partial colon; SBS-JIC, short bowel syndrome with jejuno-ileo anastomosis with intact colon; IBD, inflammatory bowel disease, 470 
CIPO, chronic intestinal pseudo-obstruction; CIF chronic intestinal failure; IVS, intravenous supplementation; FE, fluid and electrolytes alone; PN, parenteral 471 
nutrition-admixture 472 
 473 
Table 7. Multivariate analysis of factors associated with the likelihoods of major HPN/IF complications in adult patients with CIF 474 
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Presence of IFALD-cholestasis/impending 
or overt liver failure 
 Presence of CVC-vein thrombosis  Occurrence of CRBSI 
  
Association with  
IVS type (n.91) 
Association with 
PN volume (n.88) 
 
Association with  
IVS type (n.49) 
Association with   
PN volume (n.47) 
 
Association with  
IVS type (n.257) 
Association with 
PN volume (n.244) 
Independent factors  P OR P OR  P OR P OR  P OR P OR 
                
IVs type and volume                 
Total FE1  Comparator     Comparator     Comparator    
PN1 (≤1 L)  0.831  Comparator   0.246  Comparator   0.362  Comparator  
PN2 (1-2 L)  0.227  0.175   0.380  0.530   0.024 2.079 0.071  
PN3 (2-3 L)  0.017 4.437 0.004 3.881  0.746  0.183   0.015 2.264 0.043 1.654 
PN4 (>3 L)  0.007 5.692 0.001 5.008  0.827  0.329   <0.001 3.543 0.001 2.614 
                
Gender                
Male  Comparator               
Female  0.121  0.205   0.482  0.326   0.658  0.566  
 
               
Age (years)                
≤29  Comparator              
30-49  0.486  0.499   0.329  0.392   0.046 0.620 0.047 0.616 
50-69  0.358  0.306   0.228  0.217   0.005 0.507 0.007 0.516 
≥70  0.637  0.615   0.419  0.482   0.058  0.093  
                
BMI (kg/m2)                
18.5-25  Comparator              
≤15  0.916  0.947   0.188  0.183   0.834  0.806  
15-18.5  0.116  0.196   0.011 2.643 0.009 2.746  0.569  0.785  
25-30  0.152  0.220   0.757  0.713   0.054  0.117  
≥30  0.404  0.310   0.123  0.064   0.001 2.583 0.012 2.199 
                
Duration of HPN (years)                
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≤1  Comparator              
1-3  0.94  0.867   0.405 1.573 0.227 2.006  0.426  0.317  
3-10  0.839  0.667   0.054 2.540 0.035 3.025  0.669  0.798  
>10  0.949  0.931   0.036 3.105 0.019 3.873  0.516  0.405  
                
Mechanism of IF                
SBS-J  Comparator              
SBS-JC  0.190  0.23   0.215  0.168   0.722  0.994  
SBS-JIC  0.434  0.513   0.874  0.969   0.191  0.180  
Fistulas   0.304  0.421   0.578  0.678   0.542  0.603  
Dysmotility  0.026 0.314 0.036 0.330  0.654  0.590   0.290  0.428  
Obstruction   0.917  0.878   0.470  0.563   0.470  0.558  
Mucosal disease  0.526  0.556   0.948  0.895   0.769  0.972  
 
               
Underlying disease                
Total IBD  Comparator              
Total CIPO  0.510  0.598   0.889  0.848   0.041 1.982 0.074  
Other causes of SBS  0.581  0.686   0.077  0.156   0.080  0.132  
Miscellaneous  0.079  0.105   0.123  0.109   0.034 1.775 0.055  
Mesenteric ischemia  0.273  0.323   0.111  0.099   0.796  0.976  
Radiation enteritis  0.454  0.421   0.799  0.928   0.857  0.722  
Surgical complications  0.027 2.219 0.112   0.557  0.658   0.470  0.455  
                
BMI, body mass index; HPN, home parenteral nutrition; IF, intestinal failure; SBS-J, short bowel syndrome with jejunostomy; SBS-JC, short bowel syndrome with jejuno-colon 475 
anastomosis with partial colon; SBS-JIC, short bowel syndrome with jejuno-ileo anastomosis with intact colon; IBD, inflammatory bowel disease, CIPO, chronic intestinal 476 
pseudo-obstruction; CIF chronic intestinal failure; IVS, intravenous supplementation; FE, fluid and electrolytes alone; PN, parenteral nutrition-admixture 477 
 478 
 479 
